ACMG/AMP classification system with SVI recommendations (t2)
Standard ACMG/AMP classification system applied with current Sequence Variant Interpretation (SVI) recommendations and newly available annotation data, re-evaluating the same VUS cohort.
Overview
An explanatory profile has not yet been reviewed for this record.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
Model Capabilities & Hardware Requirements
Deployment facts recorded for ACMG/AMP classification system with SVI recommendations (t2). Fields the record does not carry are marked not recorded.
Evaluations and results
1 evaluation · 2 results. Different protocols are not a single leaderboard.
Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2) · Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort
Sorted by Proportion (reclassified: VUS to likely benign) (higher is better). The best value in each column is highlighted. Decimals are rounded for display; each value links to the printed value and its source.
| Tested configuration | Proportion (reclassified: VUS to likely benign) | Count (reclassified: VUS to likely benign) |
|---|---|---|
| ACMG/AMP classification system with SVI recommendations (t2)Evaluation | 20% | 24 |
All 2 result rows with coverage, uncertainty and sources
Filter evaluations
Applied filters: All linked evaluations
| Tested configuration | Protocol and dataset | Finding | Evidence and details |
|---|---|---|---|
| Configuration: ACMG/AMP classification system with SVI recommendations (t2) | Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2) Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort | 24 Count (reclassified: VUS to likely benign) count · unknown Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceBenet-Pages t2 (ACMG/AMP + SVI) reclassification of the 121-variant VUS cohort Not reported Aggregation: Not reported Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)": "Of 121 VUS, 20% (n = 24) were reclassified as LB..." |
| Configuration: ACMG/AMP classification system with SVI recommendations (t2) | Protocol: Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2) Dataset: Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification cohort | 20% Proportion (reclassified: VUS to likely benign) percent · higher Uncertainty: Not reported by the source: not reported for this endpoint Coverage: Not reported scored / Not reported eligible | Author-reported evaluation · Source checkedMethods, coverage and sourceBenet-Pages t2 (ACMG/AMP + SVI) reclassification of the 121-variant VUS cohort Not reported Aggregation: Not reported Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)": "Of 121 VUS, 20% (n = 24) were reclassified as LB..." |
Source checking is not independent reproduction. Release 2026-11-21-adc15377fab2.
Use this configuration
How it works, versions and access
Additional methodological details, versions and access terms have not yet been extracted into a structured profile for this configuration. Consult the linked sources and evaluation records below.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
Release 2026-11-21-adc15377fab2 · Record review: source checked
1 source record and release history
- Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Original source · 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Technical metadata and record identifiers
Technical metadata for this record is tracked under stable ID uc-clinical-20261005-benet-pages-acmg-svi-config.
Related records
How to cite
ACMG/AMP classification system with SVI recommendations (t2). Rewire biological model benchmark database, release 2026-11-21-adc15377fab2. https://benchmarks.rewirebio.io/database/configuration/uc-clinical-20261005-benet-pages-acmg-svi-config/
Release 2026-11-21-adc15377fab2. Rankings and values change between releases, so keep the release id in the citation. Cite the original publication as well for any value you reuse: each result links its source.
The compilation and annotations made by Rewire in this release are offered under CC BY 4.0; values and text taken from cited sources stay under the terms of those sources and are not covered by this licence. Data licence